RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

RAS proteins have traditionally been deemed undruggable, as they do not possess an
active site to which small molecules could bind but small molecules that target one form of …

RAS is the most frequently mutated oncogene in cancer and a critical driver of oncogenesis.
Therapeutic targeting of RAS has been a goal of cancer research for more than 30 years …

Simple Summary Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated
in about 25% of all human cancers and is at the center of pathways involved in …

KRAS is the most frequently mutated oncogene in human cancer. In addition to holding this
distinction, unsuccessful attempts to target this protein have led to the characterization of …

Members of the family of RAS proto-oncogenes, discovered just over 40 years ago, were
among the first cancer-initiating genes to be discovered. Of the three RAS family members …

RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …

RAS mutations are among the most common oncogenic drivers in human cancers, affecting
nearly a third of all solid tumors and around a fifth of common myeloid malignancies, but …

Activating mutations in RAS family proteins are found in~ 25% of all human cancers.
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …